5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Lupin Ltd.

•
lupin.comBSE: 500257NSE: LUPIN
Market Cap₹ 94,883 Cr.
Current Price
High / Low₹ 2,530 / 1,900
Stock P/E13.6
Book Value₹ 717
Price to Book3.52
Dividend Yield0.87 %
ROCE28.4 %
ROE23.5 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2026 • Sale of Pharmaceutical Goods: 96.9% • Other Operating Revenue: 2.4% • Income from Research Services & Sale of IPs: 0.6%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 38.3% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 21.6%
  • Operating margins have improved to 36.7% from 10.4%
  • Latest quarter profit grew 27.6% YoY, showing strong momentum

CONS

  • Recurring exceptional / one-off items are inflating headline profit
  • Though reporting repeated profits, the company pays out little dividend (12.9%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.00128.3263558.070.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3,4253,5603,9993,3324,0843,9324,0604,3835,6053,8534,4345,1527,172
2,7912,8242,8982,6962,9682,9912,7972,7402,9792,8932,8852,9533,664
Operating Profit6347361,1016361,1169401,2631,6432,6269601,5492,1993,508
OPM %18.52%20.68%27.53%19.09%27.33%23.92%31.11%37.49%46.86%24.92%34.95%42.69%48.91%
282623313833-224954663-534537102
Interest16151113141820341928363936
Depreciation140149145290141146153208177175179177190
Profit before Tax5776961,0844281,0839841,2171,5532,5881,6368682,6023,610
Tax %17.27%21.18%15.45%10.30%17.89%17.91%19.09%16.85%17.78%17.02%17.34%16.86%24.80%
Net Profit4775499163848898089851,2912,1281,3577172,1642,715
10.4812.0620.148.4319.5117.7121.5828.3046.6029.7215.7147.3559.37

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
12,75310,08811,35611,02611,05611,77211,25914,66616,96819,51320,611
8,2678,0028,5049,1189,01211,56710,29511,22711,57412,33612,394
Operating Profit4,4862,0862,8531,9082,0442059643,4395,3937,1768,216
OPM %35.18%20.68%25.12%17.30%18.49%1.74%8.56%23.45%31.79%36.78%39.86%
88131-49-2841292212101261761,346768
Interest293335534173985684121138
Depreciation366390426519503514548725648707720
Profit before Tax4,1791,7942,3421,0521,630-1625272,7854,8377,6948,716
Tax %24.83%25.04%34.30%30.86%22.77%-16.82%19.34%16.47%17.87%17.26%20.23%
Net Profit3,1411,3451,5397281,259-1894252,3263,9736,3676,953
EPS69.3529.6633.8915.9927.65-4.169.3151.0487.01139.25—
Dividend Payout %10.78%16.81%14.70%37.36%23.43%-96.34%42.80%15.67%13.79%12.93%—

COMPOUNDED SALES GROWTH

10 Years:
6%
5 Years:
12%
3 Years:
20%

COMPOUNDED PROFIT GROWTH

10 Years:
8%
5 Years:
38%
3 Years:
146%

STOCK PRICE CAGR

10 Years:
3%
5 Years:
16%
3 Years:
23%
1 Year:
5%

RETURN ON EQUITY

10 Years:
11%
5 Years:
11%
3 Years:
18%
Last Year:
23%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 17

₹ 9

Rs.18.0000 per share(900%)Final Dividend

2025

Jul 25

₹ 6

Rs.12.0000 per share (600%) Final Dividend

2024

Jul 16

₹ 4

Rs.8.0000 per share(400%)Final Dividend

2023

Jul 14

₹ 2

Rs.4.0000 per share (200%)Final Dividend

2022

Jul 14

₹ 2

Rs.4.0000 per share(200%)Final Dividend

2021

Jul 27

₹ 3.25

Rs.6.5000 per share(325%)Final Dividend

2018

Jul 30

₹ 2.50

Rs.5.0000 per share(250%)Dividend

2017

Jul 24

₹ 3.75

Rs.7.5000 per share(375%)Dividend

2016

Jul 25

₹ 3.75

Rs.7.5000 per share(375%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital90909091919191919191
14,51615,48316,80817,16818,28517,89818,17220,39924,10529,981
7041031021914819237561583001,138
Trade Payables1,4781,4281,2541,5661,1961,3521,5662,0361,9692,529
1,0591,5761,4361,6651,8052,0512,0982,2381,9672,364
Total Liabilities17,84818,68119,69020,68021,85922,31322,68424,92328,43236,103
3,0133,3413,3733,5143,6393,6904,0224,1134,9464,873
Capital Work in Progress481850904695796774738411232429
6,9145,3637,3887,4569,5639,5119,97411,58111,95515,625
2,1262,1802,3062,4852,7083,1773,0192,9693,2273,351
00000003,8425,6646,922
Cash & Bank173111611,30628465101139459128
5,1436,8375,6585,2254,8695,0974,8291,8681,9494,775
Total Assets17,84818,68119,69020,68021,85922,31322,68424,92328,43236,103

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
5,3347003,9222,6051,99931,9212,5042,4455,540
Cash from Investing-1,941725-2,865-740-2,508-372-1,269-1,599-1,766-5,649
Cash from Financing-160-987-295-368-53102-498-867-460-121
2,252-52-501,112-991-1182738218-230

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
46.9846.9646.9546.9246.9046.9046.8946.8646.85
19.3221.5022.0421.4621.2520.5021.5021.7022.42
26.7725.1024.7325.4125.5526.5525.5825.3224.65
0.010.010.010.010.000.000.000.000.00
6.926.446.266.206.286.066.036.116.08

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-08 - Lupin Limited has informed the Exchange about Schedule of Institutional Investors Meets.

2026-09-04
Press Release

2026-09-04 - Lupin Limited has informed the Exchange regarding a press release dated September 04, 2026, titled "Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP".

2026-08-28
General Updates

2026-08-28 - Lupin Limited has informed the Exchange about ESG Rating by Crisil ESG Ratings and Analytics Ltd.

2026-08-25
ESOP/ESOS/ESPS

2026-08-25 - Lupin Limited has informed the Exchange regarding Allotment of 30967 Shares.

2026-08-24
General Updates

2026-08-24 - Lupin Limited has informed the Exchange about ESG Rating by ESG Risk Assessments and Insights Limited.

2026-08-20
Arrangements for strategic, technical, manufacturing, or marketing tie up

2026-08-20 - Lupin Limited has informed the Exchange about VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

2026-08-18
Demise

2026-08-18 - Lupin Limited has informed the Exchange regarding Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

2026-08-17
Press Release

2026-08-17 - Lupin Limited has informed the Exchange regarding a press release dated August 17, 2026, titled "Lupin Announces Approval from U.S. FDA for Pitolisant Tablets".

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Lupin Limited has informed the Exchange about Transcript of Q1 FY2027 Earnings Conference Call

News

Recent coverage and analyst commentary for LUPIN

Loading news…

🤖

AI Stock Analyst

Lupin Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login